Management of chronic myeloid leukemia in blast crisis.

Abstract

Due to the high efficacy of BCR-ABL tyrosine kinase inhibition (TKI) in chronic phase (CP) chronic myeloid leukemia (CML), the frequency of blast crisis (BC) is greatly reduced compared to the pre-TKI era. However, TKI treatment of BC has only marginally improved the number of favorable responses, including remissions, which for the most part have only been transitory. Occasionally, they provide a therapeutic window to perform an allogeneic stem cell transplantation (allo-SCT). The challenge remains to improve management of BC with the limited options available. We review and summarize articles pertaining to the treatment of BC CML published after 2002. Additionally, we will discuss whether there is a need for a new definition of BC and/or treatment failure.

• Authors: S Saußele, Richard T Silver
• Journal: Annals of hematology (Ann Hematol) Vol. 94 Suppl 2 Pg. S159-65 (Apr 2015) ISSN: 1432-0584 [Electronic] Germany
• PMID: 25814082 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• BCR-ABL1 fusion protein, human
• Protein Kinase Inhibitors
• Fusion Proteins, bcr-abl

Topics

• Antineoplastic Agents (therapeutic use)
• Blast Crisis (diagnosis, etiology, prevention & control)
• Combined Modality Therapy
• Disease Progression
• Fusion Proteins, bcr-abl (antagonists & inhibitors)
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, enzymology, physiopathology, therapy)
• Practice Guidelines as Topic
• Precision Medicine
• Prognosis
• Protein Kinase Inhibitors (therapeutic use)
• Recurrence
• Transplantation, Homologous